Source prnewswire
VANTIS VASCULAR SECURES $5 MILLION IN SAFE FINANCING TO DRIVE INNOVATION IN VASCULAR INTERVENTIONS
The successful closing of a $5 million SAFE financing round, which is convertible upon Vantis' future Series C preferred round, was announced today.Vantis is on a mission to transform the way the medical community navigates and treats complex and calcific arteries.Vantis is on a mission to transform the way the medical community navigates and treats complex and calcific arteries.Funds will support the near-term commercial launch of our CrossFAST system.The CrossFAST Integrated Microcatheter Guide Extension System is one of Vantis' flagship products in development.The Chief Medical Officer at Vantis stated that cardiopulmonary interventions are becoming more challenging.The Chief Medical Officer at Vantis stated that cardiopulmonary interventions are becoming more challenging.The CrossFAST Integrated Microcatheter Guide Extension System, with 2-in-1 DuoPro Interlocking Technology, provides interventionalists with enhanced control and maneuverability to traverse the most calcific and tortuous anatomies, while the CrossSHOCK IVL System utilizes a low profile, micro electrode design to maximize theThere are currently no commercially available products for sale in any geography.About Vantis Vascular.Vantis is a medical technology company with a focus on innovation and patient-centered solutions.The company is named Vantis Vascular, Inc.
No Comments